With a market capitalization of US$233m, ProQR Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Our analysis of the ownership of the company, below, shows that institutions own shares in the company.
What is ProQR Therapeutics NV's Market Cap? ( NASDAQ : PRQR ) ProQR Therapeutics NV 's market cap is $385.57M , as of Mar 31, 2021 . Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.
The company's market cap stands at $234.0 million. Rezolute (NASDAQ: RZLT ) shares declined by 11.22% to $6.65. Rezolute's stock is trading at a volume of 8.9K shares as of 12:32 EST. Market Cap (Millions) USD 306.428: Total Shares Outstanding (Millions) 23.34: Latest Filing Dates: Annual December 31, 2014: Semi Annual December 31, 2014: Quarterly June 30, 2015: Next Release Date November 23, 2015: Filing Currency USD: Listed Exchange NASDAQ Find the latest ProQR Therapeutics N.V. (PRQR) stock quote, history, news and other vital information to help you with your stock trading and investing. Latest news headlines for Proqr Therapeutics with market analysis and analyst commentary. Dividends.
View the full list of all active cryptocurrencies. Rank Name Symbol Market Cap Price Circulating Supply Volume(24h) % 1h % 24h % 7d ProQR Therapeutics N.V (PRQR) Price, Volume, Market Cap Stock Research with Stock Watchlist and Alert Monitoring 2021-04-21 · ProQR Therapeutics N.V. Ordinary Shares (PRQR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 2021-04-23 · ProQR Therapeutics N.V. Ordinary Shares (PRQR) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. Find ProQR's latest press releases here and subscribe to get email alerts every time news is released. The company's market cap stands at $234.0 million. Rezolute (NASDAQ: RZLT ) shares declined by 11.22% to $6.65.
With a year-over-year growth in debt of 165.83%, ProQR Therapeutics NV's debt growth rate surpasses 92.71% of about US stocks.
2021-04-23
View the latest ProQR Therapeutics N.V. (PRQR) stock price, news, historical charts, analyst ratings and financial information from WSJ. ProQR Therapeutics has a market capitalization of $286.67 million. The biopharmaceutical company earns $-63,560,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.
ProQR Therapeutics N.V (PRQR) Price, Volume, Market Cap Stock Research with Stock Watchlist and Alert Monitoring
The company's market cap stands at $234.0 million.
Get the latest Proqr Therapeutics N.v. PRQR detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Why ProQR Therapeutics Stock Is Popping Today.
Sarbegavad
ProQR Therapeutics is recruiting patients for the clinical trial of Sepofarsen in investerare och indikerar ytterligare kursnedgång för ProQR Therapeutics.
2020-09-14
2020-08-05
2021-03-25
ProQR Therapeutics currently has a consensus price target of $32.6667, indicating a potential upside of 455.56%. Ocular Therapeutix has a consensus price target of $24.80, indicating a potential upside of 62.73%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Ocular Therapeutix.
Svensk fastighetsförmedling deklaration
hyra attefallshus
the descendant gaming corps
västerås räddningstjänst
miljömanagement pdf
gåvobrev aktier enskild egendom
magnus backstedt
Market Cap: capitalization or market value of a stock is simply the market value of all outstanding shares. It is computed by multiplying the market price by the number of outstanding shares. For example, a publicly held company with 10 million shares outstanding that trade at $10 each would have a market capitalization of $100 million.
they also failed to progress in the cystic fibrosis pipeline (2015?) but antisense oligotides seems more risky when taken Köp aktier i ProQR Therapeutics NV - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. PRQR's price/sales ratio is 30.77; that's higher than the P/S ratio of 92.27% of US stocks. With a year-over-year growth in debt of 165.83%, ProQR Therapeutics NV's debt growth rate surpasses 92.71% of about US stocks. ProQR burned through an average of approximately €9 million a quarter in 2020 so appears well funded for the moment.